3Gφtzsche PC, Hammarquist C, Burr M. House dust mite control measures in the management of asthma: meta-analysis. BMJ, 1998, 317 : 1105-1110. 被引量：1
4Hedlin G, Graff-Lonnevig V, Heilbom H, et al. Immunotherapy with cat-and dog-dander extracts. V. Effects of 3 years of treatment. J Allergy Clin Immunol, 1991, 87:955-964. 被引量：1
5Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med, 1999,341:468-475. 被引量：1
6Maasch H J, Wahl R. Preparation of human serum pools for allergen specific IgE : criteria for selection and reproducibility. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M, 1988, (82) :117-127. 被引量：1
7Nelson HS. The use of standardized extracts in allergen immunotherapy. J Allergy Clin Immunol, 2000, 106:41-45. 被引量：1
8Alvarez-Cuesta E, Bousquet J, Canonica GW, et al. Standards for practical allergen-specific immunotherapy. Allergy, 2006, 61 Suppl 82 : 1-20. 被引量：1
9Canonica GW, Baena-Cagnani CE, Bousquet J, et al. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization ( WAO ) taskforce. Allergy, 2007, 62:317-324. 被引量：1
10Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update ( in collaboration with the World Health Organization, GA ( 2 ) LEN and AllerGen). Allergy, 2008, 63 Suppl 86:8-160. 被引量：1
